TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07833735: An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SYS6043 With or Without Bevacizumab, With or Without Chemotherapy in

Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 400 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT07833735 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07833735 Rescue Dossier →